Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.35 USD | -1.61% | -5.16% | +8.89% |
13/05 | Trending : Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal | DJ |
13/05 | Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.89% | 46Cr | |
+26.37% | 4.82TCr | |
-1.01% | 4.17TCr | |
+43.79% | 4.1TCr | |
-5.31% | 2.88TCr | |
+9.34% | 2.56TCr | |
-21.69% | 1.9TCr | |
+6.23% | 1.29TCr | |
+26.99% | 1.2TCr | |
-3.38% | 1.18TCr |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Fulcrum Therapeutics Completes Patient Enrollment for Phase 3 Study of Losmapimod